title: Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.
abstract: Intensification therapy adding a boosted protease inhibitor (PI) to a failing regimen has the potential to worsen the resistance profile. Sixty-six patients included in four different boosted PI intensification studies were assessed and resistance mutations in the reverse transcriptase and protease genes were evaluated at baseline and 4 weeks after the initiation of the intensification strategy. Only one of the 66 patients developed changes in their pattern of mutations able to generate or increase resistance to new drugs.
authors.affiliation: Infectious Diseases Service, IDIBAPS, Hospital Clínic, Faculty of Medicine, University of Barcelona, Barcelona, Spain.
authors.forename: José L
authors.initials: JL
authors.lastname: Blanco
authors.forename: M Alejandra
authors.initials: MA
authors.lastname: Biglia
authors.forename: Mireia
authors.initials: M
authors.lastname: Arnedo
authors.forename: Esteban
authors.initials: E
authors.lastname: Martínez
authors.forename: Josep
authors.initials: J
authors.lastname: Mallolas
authors.forename: Ana
authors.initials: A
authors.lastname: Milinkovic
authors.forename: Montserrat
authors.initials: M
authors.lastname: Laguno
authors.forename: Maria
authors.initials: M
authors.lastname: Larrousse
authors.forename: Agathe
authors.initials: A
authors.lastname: Leon
authors.forename: Montserrat
authors.initials: M
authors.lastname: Lonca
authors.forename: Felipe
authors.initials: F
authors.lastname: García
authors.forename: José M
authors.initials: JM
authors.lastname: Miró
authors.forename: Tomás
authors.initials: T
authors.lastname: Pumarola
authors.forename: José M
authors.initials: JM
authors.lastname: Gatell
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D002219:Carbamates; D024921:Drug Resistance, Multiple, Viral; D005500:Follow-Up Studies; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D016333:HIV Protease / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D054303:HIV Reverse Transcriptase / Q000235:genetics*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D019469:Indinavir / Q000627:therapeutic use; D061466:Lopinavir; D009154:Mutation; D011744:Pyrimidinones / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D019258:Saquinavir / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D017211:Treatment Failure; D019562:Viral Load
chemical_list: D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D013449:Sulfonamides; D061466:Lopinavir; C095108:amprenavir; D019469:Indinavir; D054303:HIV Reverse Transcriptase; D016333:HIV Protease; D019258:Saquinavir; D019438:Ritonavir